Literature DB >> 33754073

The subcellular redistribution of NLRC5 promotes angiogenesis via interacting with STAT3 in endothelial cells.

Xu Xu1, Yefei Shi1, Peipei Luan1, Wenxin Kou1, Bo Li1, Ming Zhai1, Shuangjie You1, Qing Yu1, Jianhui Zhuang1, Weixia Jian2, Mark W Feinberg3, Wenhui Peng1.   

Abstract

Angiogenesis is a critical step in repair of tissue injury. The pattern recognition receptors (PRRs) recognize pathogen and damage associated molecular patterns (DAMPs) during injury and achieve host defense directly. However, the role of NLR family CARD domain containing 5 (NLRC5), an important member of PPRs, beyond host defense in angiogenesis during tissue repair remains unknown.
Methods: In vitro, western blot and real-time PCR (RT-PCR) were used to detect the expression of NLRC5 in endothelial cells (ECs). Immunofluorescence microscopy was used to reveal the subcellular location of NLRC5 in ECs. Cell proliferation, wound healing, tube formation assays of ECs were performed to study the role of NLRC5 in angiogenesis. By using Tie2Cre-NLRC5flox/flox mice and bone marrow transplantation studies, we defined an EC-specific role for NLRC5 in angiogenesis. Mechanistically, co-immunoprecipitation studies and RNA sequencing indicated that signal transducer and activator of transcription 3 (STAT3) was the target of NLRC5 in the nucleus. And Co-IP was used to verify the specific domain of NLRC5 binding with STAT3. ChIP assay determined the genes regulated by interaction of STAT3 and NLRC5.
Results: Knockdown of NLRC5 in vitro or in vivo inhibited pathological angiogenesis, but had no effect on physiological angiogenesis. NLRC5 was also identified to bind to STAT3 in the nucleus required the integrated death-domain and nucleotide-binding domain (DD+NACHT domain) of NLRC5. And the interaction of STAT3 and NLRC5 could enhance the transcription of angiopoietin-2 (Ang2) and cyclin D1 (CCND1) to participate in angiogenesis. Conclusions: In the ischemic microenvironment, NLRC5 protein accumulates in the nucleus of ECs and enhances STAT3 transcriptional activity for angiogenesis. These findings establish NLRC5 as a novel modulator of VEGFA signaling, providing a new target for angiogenic therapy to foster tissue regeneration. © The author(s).

Entities:  

Keywords:  NLRC5; STAT3; angiogenesis; endothelial cell; signal transduction

Mesh:

Substances:

Year:  2021        PMID: 33754073      PMCID: PMC7977449          DOI: 10.7150/thno.54473

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  75 in total

1.  Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes.

Authors:  Jinbo Yang; Jing Huang; Maupali Dasgupta; Nathan Sears; Masaru Miyagi; Benlian Wang; Mark R Chance; Xing Chen; Yuping Du; Yuxin Wang; Lizhe An; Qin Wang; Tao Lu; Xiaodong Zhang; Zhenghe Wang; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-23       Impact factor: 11.205

2.  Calpastatin counteracts pathological angiogenesis by inhibiting suppressor of cytokine signaling 3 degradation in vascular endothelial cells.

Authors:  Takuro Miyazaki; Yoshitaka Taketomi; Yuta Saito; Tomohiko Hosono; Xiao-Feng Lei; Joo-Ri Kim-Kaneyama; Satoru Arata; Haruo Takahashi; Makoto Murakami; Akira Miyazaki
Journal:  Circ Res       Date:  2015-02-03       Impact factor: 17.367

3.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Authors:  Sayuri Yoshihama; Jason Roszik; Isaac Downs; Torsten B Meissner; Saptha Vijayan; Bjoern Chapuy; Tabasum Sidiq; Margaret A Shipp; Gregory A Lizee; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

4.  Mechanical regulation of vascular growth and tissue regeneration in vivo.

Authors:  Joel D Boerckel; Brent A Uhrig; Nick J Willett; Nathaniel Huebsch; Robert E Guldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

5.  NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.

Authors:  Francesco Staehli; Kristina Ludigs; Leonhard X Heinz; Queralt Seguín-Estévez; Isabel Ferrero; Marion Braun; Kate Schroder; Manuele Rebsamen; Aubry Tardivel; Chantal Mattmann; H Robson MacDonald; Pedro Romero; Walter Reith; Greta Guarda; Jürg Tschopp
Journal:  J Immunol       Date:  2012-03-12       Impact factor: 5.422

6.  FNDC5/Irisin inhibits pathological cardiac hypertrophy.

Authors:  Qing Yu; Wenxin Kou; Xu Xu; Shunping Zhou; Peipei Luan; Xiaopeng Xu; Hailing Li; Jianhui Zhuang; Jun Wang; Yifan Zhao; Yawei Xu; Wenhui Peng
Journal:  Clin Sci (Lond)       Date:  2019-03-01       Impact factor: 6.124

7.  NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression.

Authors:  Torsten B Meissner; Yuen-Joyce Liu; Kyoung-Hee Lee; Amy Li; Amlan Biswas; Marja C J A van Eggermond; Peter J van den Elsen; Koichi S Kobayashi
Journal:  J Immunol       Date:  2012-04-06       Impact factor: 5.422

8.  Essential role of interleukin-6 in post-stroke angiogenesis.

Authors:  Karen Gertz; Golo Kronenberg; Roland E Kälin; Tina Baldinger; Christian Werner; Mustafa Balkaya; Gina D Eom; Julian Hellmann-Regen; Jan Kröber; Kelly R Miller; Ute Lindauer; Ulrich Laufs; Ulrich Dirnagl; Frank L Heppner; Matthias Endres
Journal:  Brain       Date:  2012-04-03       Impact factor: 13.501

9.  A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis.

Authors:  Mingming Zhang; Lixing Zhou; Yuejie Xu; Min Yang; Yilai Xu; Garrison Paul Komaniecki; Tatsiana Kosciuk; Xiao Chen; Xuan Lu; Xiaoping Zou; Maurine E Linder; Hening Lin
Journal:  Nature       Date:  2020-10-07       Impact factor: 49.962

10.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB.

Authors:  Jinbo Yang; Xudong Liao; Mukesh K Agarwal; Laura Barnes; Philip E Auron; George R Stark
Journal:  Genes Dev       Date:  2007-05-17       Impact factor: 11.361

View more
  1 in total

1.  UHMK1 aids colorectal cancer cell proliferation and chemoresistance through augmenting IL-6/STAT3 signaling.

Authors:  Xuedi Gao; Wenfang Bao; Jin Bai; Kailing Fan; Li Li; Yandong Li
Journal:  Cell Death Dis       Date:  2022-05-02       Impact factor: 9.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.